Thermo Fisher Scientific (TMO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Oct, 2026Executive summary
Q3 revenue rose 9% YoY to $12,137M, with 6% organic growth; adjusted EPS increased 15% to $6.68.
Strong productivity lifted adjusted operating margin to 24.5%, up 1.2 points; management raised FY26 revenue, adjusted EPS and free cash flow guidance.
Customer activity and end-market conditions improved; growth strategy and PPI Business System supported performance.
Financial highlights
Q3 GAAP operating income rose 17% to $2,263M; adjusted operating income increased 15% to $2,968M.
GAAP diluted EPS rose 9% to $4.64; adjusted diluted EPS increased 15% to $6.68.
Q3 net income attributable to shareholders was $1,721M versus $1,616M; adjusted net income was $2,477M versus $2,190M.
9M revenue increased 9% to $35,136M; adjusted operating income rose 12% to $8,102M and adjusted EPS increased 11% to $18.15.
Adjusted gross margin was 42.8%; adjusted SG&A was 15.5% of revenue and R&D expense was $350M.
Outlook and guidance
FY26 revenue guidance rose to $47.7B-$48.2B, representing 7%-8% reported growth; organic revenue growth outlook increased to 4%.
FY26 adjusted EPS guidance rose to $25.13-$25.43, representing 10%-11% growth; adjusted operating margin expansion assumption remained 80 bps.
FY26 free cash flow guidance increased to $7B-$7.5B; net capex is expected at $1.9B-$2B.
H2 organic growth outlook increased to 5%; Q4 guidance remained 4%, with some Pharma Services activity shifted from Q4 into Q3.
Management expects progress toward a more normal growth environment by late 2027 to H1 2028; 7% organic growth is a reasonable normal-period outlook, not a ceiling.
Latest events from Thermo Fisher Scientific
- Strong Q2 growth, AI-driven demand, and reshoring trends support a robust multi-year outlook.TMO
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 revenue up 10% to $11.99B, adjusted EPS up 13%, and $1B in stock repurchases.TMO
Q2 2026 - Director nominees elected, auditor ratified, executive pay not approved; strong growth and AI focus.TMO
AGM 2026 - Targets 3–6% organic growth for 2026–2027, fueled by AI, innovation, and accretive M&A.TMO
Investor Day 2026 - Executive compensation program revised for 2026 to enhance pay-for-performance and shareholder alignment.TMO
Proxy filing - Q1 2026 revenue rose 6% to $11.01B, adjusted EPS up 6%, and guidance was raised.TMO
Q1 2026 - Q3 revenue up 5% to $11.12B, adjusted EPS up 10%, with strong innovation and acquisitions.TMO
Q3 2025 - Targets 7–9% organic growth, margin expansion, and share gains through innovation and execution.TMO
Investor Day 2024 - Q2 revenue dipped 1% but EPS grew, and guidance was raised after the Olink acquisition.TMO
Q2 2024